Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Published:2016-06 Issue:10038 Volume:387 Page:2630-2640
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Khanna Dinesh,Denton Christopher P,Jahreis Angelika,van Laar Jacob M,Frech Tracy M,Anderson Marina E,Baron Murray,Chung Lorinda,Fierlbeck Gerhard,Lakshminarayanan Santhanam,Allanore Yannick,Pope Janet E,Riemekasten Gabriela,Steen Virginia,Müller-Ladner Ulf,Lafyatis Robert,Stifano Giuseppina,Spotswood Helen,Chen-Harris Haiyin,Dziadek Sebastian,Morimoto Alyssa,Sornasse Thierry,Siegel Jeffrey,Furst Daniel E

Publisher

Elsevier BV

Subject

General Medicine

Reference40 articles.

1. Epidemiology of systemic sclerosis;Nikpour;Best Practice Res Clin Rheumatol,2010

2. Interleukin-6: a new therapeutic target in systemic sclerosis?;O'Reilly;Clin Transl Immunol,2013

3. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts;Kadono;J Rheumatol,1998

4. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis;Desallais;Arthritis Res Ther,2014

5. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis;De Lauretis;J Rheumatol,2013

Cited by 532 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: A systematic review;Autoimmunity Reviews;2024-10

2. Pathogenic role of anti‐nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases;Immunological Reviews;2024-09-09

3. Newer Therapies in Rheumatology;Medical Clinics of North America;2024-09

4. Unraveling the role of MiR‐181 in skin fibrosis pathogenesis by targeting NUDT21;The FASEB Journal;2024-09

5. Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results;Current Opinion in Rheumatology;2024-08-28